psychiatric disorders
| 6 min read
With multiple trials underway and billions in investment, psychedelic therapies are moving from experimental research toward mainstream mental health care.
| 3 min read
New research revealed that manufacturer-funded clinical trials deem drugs more effective than non-sponsored trials.
| 4 min read
The therapy met its primary endpoints in two Phase 3 studies and offers a new approach for the tens of millions of people living with the psychiatric condition.
| 10+ min read
A new type of drug for schizophrenia could finally be approved in September. Others may not be far behind.
| 10 min read
Researchers explore the role of forgetting in normal brain function and as a therapeutic target for fear-related disorders.
| 4 min read
Researchers identified schizophrenia risk genes that mediate placental, rather than brain, function, revealing new insight into the disease’s developmental origins.
| 6 min read
Amit Etkin embraces the diverse underpinnings of depression and other psychiatric disorders and pairs patients with drugs based on their unique biology.
Page 1 of 1 - 7 Total Items
